Vaccine firms in deal for overseas trials
China National Biotec Group and Sinovac Biotech Ltd said on Saturday they have each found two more countries to run late-stage clinical tests of their coronavirus vaccine candidates, as the two companies showcased their vaccines at the China International Fair for Trade in Services in Beijing.
Serbia and Pakistan have agreed to participate in the Phase 3 trials of CNBG’s vaccine candidates while Sinovac has received approval from Turkey and Bangladesh. The two companies are seeking more data from overseas as new cases in China are dwindling.
Serbia will test two vaccines developed by CNBG’s Wuhan and Beijing units, and Pakistan will test the Beijing unit’s candidate, the company said.
CNBG’s Phase 3 trials are expected to involve 50,000 people in about 10 countries, said CNBG vice president Zhang Yuntao. Trials have already begun in United Arab Emirates, Bahrain, Peru, Morocco, Argentina and Jordan.
Zhang said foreign countries have expressed interest in ordering a combined 500 million doses of its vaccines.
Sinovac’s vaccine candidate CoronaVac, being tested in Brazil and Indonesia, also obtained approvals from Turkey and Bangladesh for Phase 3 trials, Sinovac CEO Yin Weidong said on Sunday.